Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Steven Plaxe

    TitleProfessor Of Clinical
    SchoolUniversity of California, San Diego
    DepartmentReproductive Medicine
    Address9500 Gilman Drive #0987
    CA La Jolla 92093
    Phone858-822-6199
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Bean LM, Ward KK, Plaxe S, McHale MT. Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery. Am J Obstet Gynecol. 2017 Sep; 217(3):332.e1-332.e6. PMID: 28522318.
        View in: PubMed
      2. Hillman RT, Saenz CC, McHale MT, Plaxe S. Fertility preservation and survival among young women with early ovarian cancer living in US counties with gynecologic oncologist services. Int J Gynaecol Obstet. 2017 Feb 07. PMID: 28170079.
        View in: PubMed
      3. Noticewala SS, Li N, Williamson CW, Hoh CK, Shen H, McHale MT, Saenz CC, Einck J, Plaxe S, Vaida F, Yashar CM, Mell LK. Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017 Mar 15; 97(4):797-805. PMID: 28244416.
        View in: PubMed
      4. Mell LK, Sirák I, Wei L, Tarnawski R, Mahantshetty U, Yashar CM, McHale MT, Xu R, Honerkamp-Smith G, Carmona R, Wright M, Williamson CW, Kasaová L, Li N, Kry S, Michalski J, Bosch W, Straube W, Schwarz J, Lowenstein J, Jiang SB, Saenz CC, Plaxe S, Einck J, Khorprasert C, Koonings P, Harrison T, Shi M, Mundt AJ. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2). Int J Radiat Oncol Biol Phys. 2017 Mar 01; 97(3):536-545. PMID: 28126303.
        View in: PubMed
      5. Tierney NM, Saenz C, McHale M, Ward K, Plaxe S. Industry Payments to Obstetrician-Gynecologists: An Analysis of 2014 Open Payments Data. Obstet Gynecol. 2016 Feb; 127(2):376-82. PMID: 26942368.
        View in: PubMed
      6. Shah NR, Ward KK, Plaxe S, Saenz CC, McHale MT. Urinary diversions: A time to enrich surgical training? Gynecol Oncol. 2016 Jan; 140(1):120-3. PMID: 26556767.
        View in: PubMed
      7. Kurnit KC, Ward KK, McHale MT, Saenz CC, Plaxe S. Increased prevalence of comorbid conditions in women with uterine cancer. Gynecol Oncol. 2015 Sep; 138(3):731-4. PMID: 26160712.
        View in: PubMed
      8. Bober BG, Gutierrez E, Plaxe S, Groisman A, Shah SB. Combinatorial influences of paclitaxel and strain on axonal transport. Exp Neurol. 2015 Sep; 271:358-67. PMID: 26143110.
        View in: PubMed
      9. Hillman RT, Ward K, Saenz C, McHale M, Plaxe S. Barriers prevent patient access to personalized therapies identified by molecular tumor profiling of gynecologic malignancies. J Pers Med. 2015; 5(2):165-73. PMID: 26011384.
        View in: PubMed
      10. Simpson DR, Scanderbeg DJ, Carmona R, McMurtrie RM, Einck J, Mell LK, McHale MT, Saenz CC, Plaxe S, Harrison T, Mundt AJ, Yashar CM. Clinical Outcomes of Computed Tomography-Based Volumetric Brachytherapy Planning for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2015 Sep 1; 93(1):150-7. PMID: 26130230.
        View in: PubMed
      11. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe S, Walker JL, Friccius-Quecke H, Krasner CN. Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer: A Phase II Study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9. PMID: 25254563.
        View in: PubMed
      12. Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe S, von Gruenigen VE, Bruner DW, Reeve BB, Wenzel L. Recommended Patient-Reported Core Set of Symptoms and Quality-of-Life Domains to Measure in Ovarian Cancer Treatment Trials. J Natl Cancer Inst. 2014 Jul; 106(7). PMID: 25006190.
        View in: PubMed
      13. Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, Plaxe S. Bariatric surgery decreases the risk of uterine malignancy. Gynecol Oncol. 2014 Apr; 133(1):63-6. PMID: 24680593.
        View in: PubMed
      14. Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, Plaxe S. The risk of uterine malignancy is linearly associated with body mass index in a cohort of US women. Am J Obstet Gynecol. 2013 Dec; 209(6):579.e1-5. PMID: 23938608.
        View in: PubMed
      15. Kim JS, Ward KK, Shah NR, Saenz CC, McHale MT, Plaxe S. Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics. Support Care Cancer. 2013 Nov; 21(11):3103-7. PMID: 23839499.
        View in: PubMed
      16. Abbott Y, Shah NR, Ward KK, McHale MT, Alvarez EA, Saenz CC, Plaxe S. Use of psychosocial services increases after a social worker-mediated intervention in gynecology oncology patients. Health Soc Work. 2013 May; 38(2):113-21. PMID: 23865288.
        View in: PubMed
      17. Ward KK, Tancioni I, Lawson C, Miller NL, Jean C, Chen XL, Uryu S, Kim J, Tarin D, Stupack DG, Plaxe S, Schlaepfer DD. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. Clin Exp Metastasis. 2013 Jun; 30(5):579-94. PMID: 23275034.
        View in: PubMed
      18. Ward KK, Roncancio AM, Plaxe S. Women with gynecologic malignancies have a greater incidence of suicide than women with other cancer types. Suicide Life Threat Behav. 2013 Feb; 43(1):109-15. PMID: 23278597.
        View in: PubMed
      19. Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe S. Changing demographics of cervical cancer in the United States (1973-2008). Gynecol Oncol. 2012 Sep; 126(3):330-3. PMID: 22668881.
        View in: PubMed
      20. Ward KK, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe S. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol. 2012 Aug; 126(2):176-9. PMID: 22507532.
        View in: PubMed
      21. Baughn MR, Plaxe S, Weidner N. Primary squamous carcinoma of the ovary likely arising from a monodermal cystic mucinous teratoma. Ann Diagn Pathol. 2011 Dec; 15(6):446-9. PMID: 20952274.
        View in: PubMed
      22. Tipps AM, Plaxe S, Weidner N. Endometrioid carcinoma with a low-grade spindle cell component: a tumor resembling an adnexal tumor of probable Wolffian origin. Ann Diagn Pathol. 2011 Oct; 15(5):376-81. PMID: 20952275.
        View in: PubMed
      23. Plaxe S, Brooks SE, Tian C, Bloss JD, Moore DH, Long HJ. Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol. 2008 Nov; 199(5):539.e1-6. PMID: 18565487.
        View in: PubMed
      24. Plaxe S. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008 Apr; 198(4):459.e1-8; discussion 459.e8-9. PMID: 18395040.
        View in: PubMed
      25. Plaxe S, Blessing JA, Olt G, Husseinzadah N, Lentz SS, DeGeest K, Valea FA. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Chemother Pharmacol. 2002 Aug; 50(2):151-4. PMID: 12172981.
        View in: PubMed
      26. Plaxe S, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002 Feb; 84(2):241-4. PMID: 11812081.
        View in: PubMed
      27. Plaxe S, Blessing JA, Morgan MA, Carlson J. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Am J Clin Oncol. 2002 Feb; 25(1):45-7. PMID: 11823695.
        View in: PubMed
      28. Plaxe S, Blessing JA, Bookman MA, Creasman WT. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2002 Jan; 84(1):32-5. PMID: 11748972.
        View in: PubMed
      Steven's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _